Friday, 20 Oct 2017

You are here

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

  1. In RA, Smoking status recorded in 40%; cessation counseling in only 10% & was less likely when RA was controlled. https://buff.ly/2wWaHs2 
  2. ~1/3 RA pts rank their Disease activity higher than their Rheumatologist; more likely seronegative RA, those in LDAS with FM, Depression, high pain scores. https://buff.ly/2xygaK0 
  3. Higher MASEI (enthesitis) scores in PsA associated with more Joint damage, ankylosis, arthritis mutilans periostitis, axial Disease. https://buff.ly/2fU0k25 
  4. Review shows antiphopholipid Abs associated with and increased risk of idiopathic pulm arterial HTN, left-side valvular heart dz https://t.co/79KG9Qfb6k
  5. CDC: STDs new record high #s in 2016 - chlamydia (1.6mil), gonorrhea (470k) & syphilis (28k); more screening urged https://t.co/U6bsHAeWQa
  6. In Australia from 2015 to 2030, OA numbers are expected to increase 41%; RA by 37%, with cost of care rising by 37% for both. https://t.co/BNc2P4CyU3
  7. Mayo: 1996 to 2013, 58 cases of AAV in Olmstead Co - 23 GPA, 28 MPA & 7 EGPA. 60% MPO+, 30% PR3+: Prev 42.1/100,000 https://t.co/Q0n2Srmf7t
  8. Olmstead Co. Mayo Clinic study shows asthma significantly associated with increased risk of RA (adj OR 1.74) https://t.co/lcqkjGu9BK 
  9. Kevzara (sarilumab) has been recommended by UK NICE for use with MTX in adults with severe, active RA https://t.co/2fL8LDjLi3
  10. FDA Panel Backs New Zoster Subunit Vaccine
  11. Sirukumab Turned Down by FDA
  12.  Psoriasis Increases Risk of Major Adverse Cardiovascular Events  
  13. Increased Deaths in RA, Despite Decreasing Mortality Rates
  14. No Cancer Risk With Biologic Use
  15. The DownEaster Meeting – Westborough, MA  14 October 2017  
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.